NewsClick

NewsClick
  • हिन्दी
  • Politics
  • Economy
  • Covid-19
  • Science
  • Culture
  • India
  • International
  • Sports
  • Articles
  • Videos
search
menu

INTERACTIVE ELECTION MAPS

image/svg+xml
  • All Articles
  • Newsclick Articles
  • All Videos
  • Newsclick Videos
  • हिन्दी
  • Politics
  • Economy
  • Science
  • Culture
  • India
  • Sports
  • International
  • Africa
  • Latin America
  • Palestine
  • Nepal
  • Pakistan
  • Sri Lanka
  • US
  • West Asia
About us
Subscribe
Follow us Facebook - Newsclick Twitter - Newsclick RSS - Newsclick
close menu
×
For latest updates on nCOVID-19 around the world visit our INTERACTIVE COVID MAP
Covid-19
Health

COVID-19: Can Existing Vaccines Counter Virus Variants? Research Shows Mixed Results

The mutant strains of the virus – 501Y.V2, which was first detected in South Africa and B1.1.7, first found in the UK – have been studied by researchers.
Sandipan Talukdar
27 Jan 2021
covid

At a time when large-scale vaccination efforts have begun in various parts of the world, mutant variants of the SARS-CoV-2 virus – which causes COVID-19 – have cropped up. What is clear is that the virus’ mutations are more contagious than the original.

A pertinent question that arises is whether the different vaccines in use across the world can be effective against the mutant variants or not. All of the vaccines developed target the spike protein of the virus – the protein used to enter human cells. However, the mutant variants also have some changes in the spike protein as well.

Research about the same is beginning to come in, but with mixed results. While some researchers say that the current vaccines can be effective against the new variants, others say that may not be so.

The mutant strains of the virus – 501Y.V2, which was first detected in South Africa and B1.1.7, first found in the UK – have been studied by many groups. The research has primarily focused on how antibodies respond to the variants with and without vaccination. Antibodies are protein molecules in our immune system that target an invading pathogen (virus, bacteria, fungi or anything that can cause disease).

On January 19, a team of US researchers from the Howard Hughes Medical College, The Rockefeller University, reported that people who were administered either the Moderna or the Pfizer vaccine showed a modest drop in the potency of antibodies. These people were infected by the 501Y.V2 variant. The report was published in the pre-print server BioRxiv.

Similarly, a research group from the UK led by Ravindra Gupta at Cambridge University reported that people who received the Pfizer vaccine showed lowered effectiveness against the B1.1.7 variant. However, another research effort on the same lines, conducted by researchers from BioNTech – Pfizer’s partner in manufacturing the vaccine – reported that their vaccine was effective in fighting the mutant variant.

Soon, researchers at the bio-tech company Moderna in Cambridge, Massachusetts, also reported that their vaccine was effective in developing immunity against both, B1.1.7 and 501Y.V2. Their findings have been published in BioRxiv on January 25. However, notably, the study’s data set is very limited, consisting of only eight people who received two doses of the Moderna vaccine.

As a result, a judgment on the effectiveness of the vaccines remains quite elusive at this moment. Large cohort studies could be the only way to have more clarity on the topic.

Prof. Volker Thiel, who heads the Department of Virology at the University of Bern, Switzerland, shared similar concerns. According to him: “Although the vaccines target only the spike gene, they should still mount an immune response that is diverse enough that these new variants should be covered.” He, however, emphasised that more experimental studies were needed.

Most of the COVID-19 vaccines elicit a high amount of antibodies that are able to target different regions of the spike protein and so, some of these antibodies could have the ability to target variants of the novel coronavirus.

At the same time, there research shows that the antibodies generated in the body against the virus are less effective in neutralising the 501Y.V2 variant. This is primarily due to the mutations in the spike protein in the new variant. Certain mutations render the new variant the ability to escape an antibody attack. However, as pointed out by Prof. Thiel, aside from antibodies, there are other elements in the immune system which can facilitate the fight against the mutant variants.

Get the latest reports & analysis with people's perspective on Protests, movements & deep analytical videos, discussions of the current affairs in your Telegram app. Subscribe to NewsClick's Telegram channel & get Real-Time updates on stories, as they get published on our website.
COVID-19
Covid Vaccine
novel coronavirus
Coronavirus variants
B1.1.7
501Y.V2
New Variants and Vaccines
Moderna Vaccine
Pfizer Vaccine
Related Stories
Can’t let Char Dham yatra become hotspot, Uttarakhand HC takes stock of Covid preparedness

Can’t let Char Dham Yatra Become Hotspot, Uttarakhand HC Takes Stock of Covid Preparedness

Understanding the Wide Gap Between India’s Need and Supply of Covid Vaccines

Understanding the Wide Gap Between India’s Need and Supply of Covid Vaccines

Over 300 Passengers Flee Silchar Airport to Avoid Mandatory COVID Testing

Over 300 Passengers Flee Silchar Airport to Avoid Mandatory COVID Testing

COVID-19: Workers Reject PM Modi's Suggestion to Stay Put, Exodus Continues

COVID-19: Workers Reject PM Modi's Suggestion to Stay Put, Exodus Continues

remedsivir

COVID-19: The Elusive Remdesivir and a Catastrophe in Maharashtra

Oxygen cylender

COVID-19: Multiple Delhi Hospitals Allege Haryana Govt. Not Allowing Vendors to Supply Oxygen

Inter-caste Relationship: 19-year-old Girl Approaches HC

Door-to-Door Vaccination not Possible, Centre tells Bombay HC

Oxygen Cylender

Maharashtra: 22 COVID-19 Patients Die after Oxygen Leak Cuts Supply

covid vaccine

COVID-19: Private Vaccination Centres to Procure Directly from Manufacturers Starting May 1

Unemployment

India on the Brink of Unprecedented Unemployment Crisis: CMIE Report

Share on FacebookShare on TwitterShare on WhatsAppShare via EmailShare on RedditShare on KindlePrint
Share
Share on FacebookShare on TwitterShare on WhatsAppShare via EmailShare on RedditShare on KindlePrint
Share

Related Stories

Prudhviraj Rupavath

COVID-19: Fear Engulfs Telugu State Governments as Healthcare Systems Burst at Seams

23 April 2021
With the second COVID-19 wave raging across the country over the past few we
PTI

Even Single Vaccine Dose Cuts COVID-19 Infection Rate by 65%, Finds New UK Study

23 April 2021
London: A single dose of either the Oxfo
Newsclick Report

Officers, Parl. Committee Had Flagged Oxygen Supply as an Issue in April, November 2020, Report Says

23 April 2021
An Empowered Groups of Officers set up by the Centre to manage the COVID-19 reponse and the Parliame

Pagination

  • Next page ››

More

  • Even Single Vaccine Dose Cuts COVID-19 Infection Rate by 65%, Finds New UK Study

    Even Single Vaccine Dose Cuts COVID-19 Infection Rate by 65%, Finds New UK Study

  • MP: Stones Pelted at Police for Enforcing Lockdown During Ram Leela Event

    MP: Stones Pelted at Police for Enforcing Lockdown During Ram Leela Event

  • 25 COVID Patients Die at Sir Ganga Ram Hospital in Past 24 Hours

    25 COVID Patients Die at Sir Ganga Ram Hospital in Past 24 Hours

  • Maharashtra: 13 COVID Patients Die in Virar Hospital ICU Blaze

    Maharashtra: 13 COVID Patients Die in Virar Hospital ICU Blaze

  • Load More
Subscribe
connect with
about